Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
National Monitoring Update: HPV Vaccine (Gardasil)
Notice type:
3rd Party Publications
Date:
11/11/2010
Background Information Or Related Documents:
The HSE commenced the HPV Schools Immunisation Programme in May 2010 using the HPV vaccine
Gardasil
. The Irish Medicines Board (IMB) is actively monitoring experience with the use of
Gardasil
as the vaccination programme continues.
It is estimated that 60,000 doses have been distributed and approximately 45,000 doses of
Gardasil
administered up to the end of October 2010. Up to this date (31/10/2010), the IMB received a total of 64 reports of adverse events associated with use of
Gardasil
. 55 of these reports were received since the beginning of the Schools Immunisation Programme, with 9 reports received prior to this.
The majority of reports have been consistent with the expected pattern of adverse effects for the vaccine, as outlined in the product information.
This update provides an overview of the reports of suspected adverse reactions received by the IMB in association with
Gardasil
. Additional information is provided to assist with interpretation and understanding of the data.
For further information about
Gardasil
, including the product information, visit the
HPV School Immunisation
section of our website.
« Back
Date Printed: 16/05/2024